In this territory-wide study, we examined the incidence of cardiovascular events of incident heart failure, acute myocardial infarction, atrial fibrillation, or atrial flutter in cancer patients receiving PD-1 or PD-L1 inhibitors. This evidence concerns the gene PDCD1 and myocardial infarction.